{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:21:19Z","timestamp":1783336879711,"version":"3.54.6"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"DOI":"10.1007\/s12031-026-02505-0","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:25:35Z","timestamp":1774578335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Variations in the Dopaminergic Signaling Pathways and Their Implications for Antipsychotics Pharmacogenetics"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3082-3203","authenticated-orcid":false,"given":"Holiness S. A.","family":"Olasore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew O.","family":"Olawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damilare P.","family":"Asiwaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Olashore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2505_CR1","doi-asserted-by":"crossref","unstructured":"Ahn Y, Kim J, Jung K, Lee DJ, Jung JY, Eom Y, Won HH (2025) Relationship between problematic alcohol use and various psychiatric disorders: a genetically informed study. Am J Psychiatry appi-ajp","DOI":"10.1176\/appi.ajp.20240095"},{"key":"2505_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.genhosppsych.2023.05.003","volume":"83","author":"R Alisauskiene","year":"2023","unstructured":"Alisauskiene R, Johnsen E, Gjestad R, Kroken RA, Kjelby E, Sinkeviciute I, Fathian F, Joa I, Reitan SK, Rettenbacher M, L\u00f8berg EM (2023) Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study. Gen Hosp Psychiatry 83:185\u2013193. https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.05.003","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"2505_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/fcp.12424","volume":"33","author":"CG Alladi","year":"2019","unstructured":"Alladi CG, RajKumar RP, Adithan S, Marie-Claire C, Bellivier F, Shewade DG (2019) Dopamine (DRD 2) and serotonin (HTR 2A, 2C) receptor gene polymorphisms do not influence early response to risperidone in South Indian patients with schizophrenia. Fundam Clin Pharmacol 33(3):355\u2013364","journal-title":"Fundam Clin Pharmacol"},{"key":"2505_CR4","doi-asserted-by":"crossref","unstructured":"Alvarez-Herrera S, Rosel Vales M, P\u00e9rez-S\u00e1nchez G, Becerril-Villanueva E, Flores-Medina Y, Maldonado-Garc\u00eda JL, Pav\u00f3n L (2024) Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. Pharmaceuticals\u00a017(2):167","DOI":"10.3390\/ph17020167"},{"key":"2505_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00314","volume":"10","author":"D Amato","year":"2019","unstructured":"Amato D, Kruyer A, Samaha AN, Heinz A (2019) Hypofunctional dopamine uptake and antipsychotic treatment-resistant schizophrenia. Front Psychiatry 10:314","journal-title":"Front Psychiatry"},{"issue":"9","key":"2505_CR6","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/s41380-018-0114-5","volume":"25","author":"D Amato","year":"2020","unstructured":"Amato D, Canneva F, Cumming P, Maschauer S, Groos D, Dahlmanns JK, Gr\u00f6mer TW, Chiofalo L, Dahlmanns M, Zheng F, Kornhuber J, Prante O, Alzheimer C, Von H\u00f6rsten S, M\u00fcller CP (2020) A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry 25(9):2101\u20132118","journal-title":"Mol Psychiatry"},{"issue":"2","key":"2505_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.paid.2012.08.014","volume":"54","author":"KM Beaver","year":"2013","unstructured":"Beaver KM, Wright JP, Boutwell BB, Barnes JC, DeLisi M, Vaughn MG (2013) Exploring the association between the 2-repeat allele of the MAOA gene promoter polymorphism and psychopathic personality traits, arrests, incarceration, and lifetime antisocial behavior. Pers Individ Differ 54(2):164\u2013168","journal-title":"Pers Individ Differ"},{"issue":"1","key":"2505_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","volume":"40","author":"I Besnard","year":"2013","unstructured":"Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C (2013) Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encephale 40(1):86\u201394","journal-title":"Encephale"},{"key":"2505_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2025.101927","author":"SB Bird","year":"2025","unstructured":"Bird SB (2025) Antipsychotic-induced hyperprolactinemia: toxicologic mechanism and the increased breast cancer risk. Toxicol Rep. https:\/\/doi.org\/10.1016\/j.toxrep.2025.101927","journal-title":"Toxicol Rep"},{"issue":"1","key":"2505_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","volume":"29","author":"JR Bostwick","year":"2009","unstructured":"Bostwick JR, Guthrie SK, Ellingrod VL (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29(1):64\u201373","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2505_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/070674371405900203","volume":"59","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Kennedy JL, M\u00fcller DJ (2014) Pharmacogenetics of antipsychotics. Can J Psychiatry 59(2):76\u201388","journal-title":"Can J Psychiatry"},{"key":"2505_CR12","doi-asserted-by":"crossref","unstructured":"Brasso C, Colli G, Sgro R, Bellino S, Bozzatello P, Montemagni C, Rocca P (2023) Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines, 11(3):921","DOI":"10.3390\/biomedicines11030921"},{"key":"2505_CR13","volume":"5","author":"R Brisch","year":"2014","unstructured":"Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein H-G, Steiner J, Bogerts B, Braun K, Jankowski Z, Kumaratilake J (2014) The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 5:47","journal-title":"Front Psychiatry"},{"issue":"1","key":"2505_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01771-3","volume":"12","author":"J Cabana-Dom\u00ednguez","year":"2022","unstructured":"Cabana-Dom\u00ednguez J, Torrico B, Reif A, Fern\u00e0ndez-Castillo N, Cormand B (2022) Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders. Transl Psychiatry 12(1):11","journal-title":"Transl Psychiatry"},{"key":"2505_CR15","unstructured":"Calabrese J, Al Khalili Y (2023) Psychosis. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546579\/"},{"issue":"5","key":"2505_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","volume":"19","author":"CA Calarge","year":"2009","unstructured":"Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA (2009) Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19(5):373\u2013382","journal-title":"Pharmacogenet Genomics"},{"issue":"1\u20132","key":"2505_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2005.03.005","volume":"41","author":"ML Chen","year":"2007","unstructured":"Chen ML, Chen CH (2007) Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. J Psychiatr Res 41(1\u20132):57\u201362","journal-title":"J Psychiatr Res"},{"key":"2505_CR18","doi-asserted-by":"crossref","unstructured":"Chen CY, Yeh YW, Kuo SC, Ho PS, Liang CS, Yen CH, Huang SY (2016) Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Psychoneuroendocrinology\u00a065:67\u201375","DOI":"10.1016\/j.psyneuen.2015.12.003"},{"issue":"1","key":"2505_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4398-6","volume":"12","author":"I Chikowe","year":"2019","unstructured":"Chikowe I, Domingo M, Mwakaswaya V, Parveen S, Mafuta C, Kampira E (2019) Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. BMC Res Notes 12(1):376","journal-title":"BMC Res Notes"},{"issue":"7","key":"2505_CR20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1021\/acschemneuro.8b00159","volume":"9","author":"TC Chopko","year":"2018","unstructured":"Chopko TC, Lindsley CW (2018) Classics in chemical neuroscience: risperidone. ACS Chem Neurosci 9(7):1520\u20131529","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"2505_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/JCP.0b013e31825370f4","volume":"32","author":"TS Chung","year":"2012","unstructured":"Chung TS (2012) Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. J Clin Psychopharmacol 32(3):394\u2013397","journal-title":"J Clin Psychopharmacol"},{"key":"2505_CR22","doi-asserted-by":"crossref","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, Tiihonen J (2022). Mortality in people with schizophrenia: a systematic review and meta\u2010analysis of relative risk and aggravating or attenuating factors. World Psychiatry, 21(2):248\u2013271.","DOI":"10.1002\/wps.20994"},{"key":"2505_CR23","doi-asserted-by":"crossref","unstructured":"Cotes RO, Janjua AU, Broussard B, Lazris D, Khan A, Jiao Y., Goldsmith DR (2022) A comparison of attitudes, comfort, and knowledge of clozapine among two diverse samples of US psychiatrists.\u00a0Community Ment Health J\u00a058(3):517\u2013525","DOI":"10.1007\/s10597-021-00847-0"},{"issue":"14","key":"2505_CR24","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2165\/00003495-200161140-00014","volume":"61","author":"MP Curran","year":"2001","unstructured":"Curran MP, Perry CM (2001) Amisulpride: a review of its use in the management of schizophrenia. Drugs 61(14):2123\u20132150. https:\/\/doi.org\/10.2165\/00003495-200161140-00014","journal-title":"Drugs"},{"key":"2505_CR25","unstructured":"De Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Sepp\u00e4l\u00e4 N, M\u00fcller D J (2022) An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry\u00a055(02):73\u201386"},{"key":"2505_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1274214","volume":"14","author":"M Elias","year":"2023","unstructured":"Elias M, Gombert A, Siddiqui S, Yu S, Jin Z, Bergese S (2023) Perioperative utility of amisulpride and dopamine receptor antagonist antiemetics-a narrative review. Front Pharmacol 14:1274214. https:\/\/doi.org\/10.3389\/fphar.2023.1274214","journal-title":"Front Pharmacol"},{"key":"2505_CR27","first-page":"1","volume":"8","author":"D Erdag","year":"2018","unstructured":"Erdag D, Merhan O, Yildiz B (2018) Biochemical and pharmacological properties of biogenic amines. Biog Amines 8:1\u201314","journal-title":"Biog Amines"},{"issue":"1","key":"2505_CR28","first-page":"129","volume":"29","author":"A Ermis","year":"2015","unstructured":"Ermis A, Erkiran M, Dasdemir S, Turkcan AS, Ceylan ME, Bireller ES, Cakmakoglu B (2015) The relationship between catechol-O-methyltransferase gene Val158Met (COMT) polymorphism and premorbid cannabis use in Turkish male patients with schizophrenia. In Vivo 29(1):129\u2013132","journal-title":"In Vivo"},{"issue":"10","key":"2505_CR29","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/ene.13376","volume":"24","author":"SA Factor","year":"2017","unstructured":"Factor SA, McDonald WM, Goldstein FC (2017) The role of neurotransmitters in the development of Parkinson\u2019s disease-related psychosis. Eur J Neurol 24(10):1244\u20131254","journal-title":"Eur J Neurol"},{"issue":"1","key":"2505_CR30","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.13","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sab\u00e9 M, Gaebel W (2021) EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry 64(1):e21","journal-title":"Eur Psychiatry"},{"issue":"6","key":"2505_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/tpj.2009.26","volume":"9","author":"P Gass\u00f3","year":"2009","unstructured":"Gass\u00f3 P, Mas S, Bernardo M, \u00c1lvarez S, Parellada E, Lafuente A (2009) A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 9(6):404\u2013410","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"2505_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/ijnp\/pyaa004","volume":"23","author":"M G\u00f3mez-Revuelta","year":"2020","unstructured":"G\u00f3mez-Revuelta M, Pelayo-Ter\u00e1n JM, Juncal-Ruiz M, V\u00e1zquez-Bourgon J, Su\u00e1rez-Pinilla P, Romero-Jim\u00e9nez R, Crespo-Facorro B (2020) Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol 23(4):217\u2013229","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"2505_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111336","volume":"8","author":"D Grajales","year":"2019","unstructured":"Grajales D, Ferreira V, Valverde \u00c1M (2019) Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells 8(11):1336","journal-title":"Cells"},{"issue":"24","key":"2505_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249532","volume":"21","author":"D Grinchii","year":"2020","unstructured":"Grinchii D, Dremencov E (2020) Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci 21(24):9532","journal-title":"Int J Mol Sci"},{"key":"2505_CR35","doi-asserted-by":"crossref","unstructured":"Han J, Li Y, Wang X (2017) Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia.\u00a0Neuropsychiatr Dis Treat pp. 2935\u20132943","DOI":"10.2147\/NDT.S148824"},{"key":"2505_CR36","doi-asserted-by":"crossref","unstructured":"He H, Wu H, Yang L, Gao F, Fan Y, Feng J, Ma X (2016) Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis.\u00a0Neuropsychiatr Dis Treat pp. 3129\u20133144","DOI":"10.2147\/NDT.S118614"},{"issue":"6","key":"2505_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/FPC.0b013e3283397d06","volume":"20","author":"CJ Hong","year":"2010","unstructured":"Hong CJ, Liou YJ, Bai YM, Chen TT, Wang YC, Tsai SJ (2010) Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics 20(6):359\u2013366","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"2505_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biopsych.2016.07.014","volume":"81","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81(1):9\u201320","journal-title":"Biol Psychiatry"},{"key":"2505_CR39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neulet.2014.08.041","volume":"584","author":"R Huo","year":"2015","unstructured":"Huo R, Wei Z, Xiong Y, Jiang J, Liu Y, Yan Y, Qin S (2015) Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients. Neurosci Lett 584:178\u2013183","journal-title":"Neurosci Lett"},{"issue":"4","key":"2505_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/schbul\/sby140","volume":"45","author":"M Ikeda","year":"2019","unstructured":"Ikeda M, Takahashi A, Kamatani Y, Momozawa Y, Saito T, Kondo K, Shimasaki A, Kawase K, Sakusabe T, Iwayama Y, Toyota T, Wakuda T, Kikuchi M, Kanahara N, Yamamori H, Yasuda Y, Watanabe Y, Hoya S, Aleksic B, Kushima I, Iwata N (2019) Genome-wide association study detected novel susceptibility genes for schizophrenia and shared trans-populations\/diseases genetic effect. Schizophr Bull 45(4):824\u2013834. https:\/\/doi.org\/10.1093\/schbul\/sby140","journal-title":"Schizophr Bull"},{"issue":"6","key":"2505_CR41","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.pnpbp.2004.05.015","volume":"28","author":"SH Jeong","year":"2004","unstructured":"Jeong SH, Joo E-J, Ahn YM, Kim YS (2004) Association study of dopamine transporter gene and schizophrenia in Korean population using multiple single nucleotide polymorphism markers. Prog Neuro-Psychopharmacol Biol Psychiatry 28(6):975\u2013983","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"11","key":"2505_CR42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","volume":"7","author":"E Johnsen","year":"2020","unstructured":"Johnsen E, Kroken RA, L\u00f8berg EM, Rettenbacher M, Joa I, Larsen TK, Reitan SK, Walla B, Alisauskiene R, Anda LG, Bartz-Johannessen C, Berle J\u00d8, Bjarke J, Fathian F, Hugdahl K, Kjelby E, Sinkeviciute I, Skrede S, Stabell L, Steen VM, Fleischhacker WW (2020) Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. The lancet. Psychiatry 7(11):945\u2013954. https:\/\/doi.org\/10.1016\/S2215-0366(20)30341-2","journal-title":"The lancet. Psychiatry"},{"key":"2505_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.806618","volume":"15","author":"J Jones-Tabah","year":"2022","unstructured":"Jones-Tabah J, Mohammad H, Paulus EG, Clarke PB, H\u00e9bert TE (2022) The signaling and pharmacology of the dopamine D1 receptor. Front Cell Neurosci 15:806618","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"2505_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/JCP.0000000000000294","volume":"35","author":"SG Kang","year":"2015","unstructured":"Kang SG, Na KS, Lee HJ, Chee IS, Lee K, Lee J (2015) DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks\u2019 amisulpride treatment. J Clin Psychopharmacol 35(2):158\u2013162","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2505_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/hup.1130","volume":"25","author":"SG Kang","year":"2010","unstructured":"Kang SG, Park YM, Choi JE, Lim SW, Lee HJ, Lee SH, Kim L (2010) Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol Clin Exp 25(5):397\u2013403","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"5","key":"2505_CR46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40263-020-00718-4","volume":"34","author":"N Keks","year":"2020","unstructured":"Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G (2020) Comparative tolerability of dopamine D2\/3 receptor partial agonists for schizophrenia. CNS Drugs 34(5):473\u2013507","journal-title":"CNS Drugs"},{"key":"2505_CR47","doi-asserted-by":"crossref","unstructured":"Kelly DL, Freudenreich O, Sayer MA, Love RC (2018) Addressing barriers to clozapine underutilization: a national effort","DOI":"10.1176\/appi.ps.201700162"},{"issue":"1","key":"2505_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0071-9","volume":"8","author":"JP Kesby","year":"2018","unstructured":"Kesby JP, Eyles DW, McGrath JJ, Scott JG (2018) Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry 8(1):30","journal-title":"Transl Psychiatry"},{"issue":"1","key":"2505_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nic.2019.09.007","volume":"30","author":"MS Keshavan","year":"2020","unstructured":"Keshavan MS, Collin G, Guimond S, Kelly S, Prasad KM, Lizano P (2020) Neuroimaging in schizophrenia. Neuroimaging Clin N Am 30(1):73. https:\/\/doi.org\/10.1016\/j.nic.2019.09.007","journal-title":"Neuroimaging Clin N Am"},{"key":"2505_CR50","doi-asserted-by":"publisher","unstructured":"Kibitov AA, Kiryanova EM, Salnikova LI, Bure IV, Shmukler AB, Kibitov AO (2022) The ANKK1\/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.\u00a0Drug Metab Pers Ther\u00a038(2):133\u2013142. https:\/\/doi.org\/10.1515\/dmpt-2022-0143","DOI":"10.1515\/dmpt-2022-0143"},{"issue":"3","key":"2505_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neulet.2006.07.030","volume":"405","author":"P Kirsch","year":"2006","unstructured":"Kirsch P, Reuter M, Mier D, Lonsdorf T, Stark R, Gallhofer B, Hennig J (2006) Imaging gene\u2013substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett 405(3):196\u2013201","journal-title":"Neurosci Lett"},{"issue":"3","key":"2505_CR52","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/JCP.0000000000001679","volume":"43","author":"E Kjelby","year":"2023","unstructured":"Kjelby E, Gjestad R, Fathian F, Sinkeviciute I, Alisauskiene R, Anda L, L\u00f8berg EM, Reitan SK, Joa I, Larsen TK, Rettenbacher M, Berle J\u00d8, Fasmer OB, Kroken RA, Johnsen E (2023) Antidepressive effectiveness of amisulpride, aripiprazole, and olanzapine in patients with schizophrenia spectrum disorders: a secondary outcome analysis of a pragmatic, randomized trial (BeSt InTro). J Clin Psychopharmacol 43(3):246\u2013258. https:\/\/doi.org\/10.1097\/JCP.0000000000001679","journal-title":"J Clin Psychopharmacol"},{"key":"2505_CR53","doi-asserted-by":"publisher","unstructured":"Koller D, Belmonte C, Saiz-Rodr\u00edguez M, Zubiaur P, Rom\u00e1n M, Ochoa D, Abad-Santos F (2020) Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.\u00a0Basic Clin Pharmacol Toxicol 126(3):236\u2013246. https:\/\/doi.org\/10.1111\/bcpt.13323","DOI":"10.1111\/bcpt.13323"},{"issue":"7","key":"2505_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","volume":"268","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268(7):625\u2013639. https:\/\/doi.org\/10.1007\/s00406-018-0869-3","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"2505_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.24869\/psyd.2018.157","volume":"30","author":"AA Kurylev","year":"2018","unstructured":"Kurylev AA, Brodyansky VM, Andreev BV, Kibitov AO, Limankin OV, Mosolov SN (2018) The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study). Psychiatr Danub 30(2):157\u2013163","journal-title":"Psychiatr Danub"},{"issue":"12","key":"2505_CR56","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","volume":"18","author":"JS Kwon","year":"2008","unstructured":"Kwon JS, Kim E, Kang DH, Choi JS, Yu KS, Jang IJ, APLUS Study Group (2008) Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 18(12):897\u2013907","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"2505_CR57","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nm0495-337","volume":"1","author":"BR Lawford","year":"1995","unstructured":"Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, Noble EP (1995) Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1(4):337\u2013341","journal-title":"Nat Med"},{"issue":"1","key":"2505_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.schres.2004.08.020","volume":"73","author":"BR Lawford","year":"2005","unstructured":"Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, Morris CP (2005) The C\/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophr Res 73(1):31\u201337","journal-title":"Schizophr Res"},{"issue":"9","key":"2505_CR59","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/FPC.0b013e32833ca24b","volume":"20","author":"T Lencz","year":"2010","unstructured":"Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20(9):569\u2013572","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"2505_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-024-00673-x","volume":"18","author":"H\u00c7 Lenk","year":"2024","unstructured":"Lenk H\u00c7, Koch E, O\u2019Connell KS, Smith RL, Akkouh IA, Djurovic S, Andreassen OA, Molden E (2024) Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment. Hum Genomics 18(1):108. https:\/\/doi.org\/10.1186\/s40246-024-00673-x","journal-title":"Hum Genomics"},{"issue":"4","key":"2505_CR61","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/bcp.15043","volume":"88","author":"J Li","year":"2022","unstructured":"Li J, Tang F, Si S, Wang B, Xue F (2022) Integration analysis of GWAS and expression quantitative trait loci to identify candidate genes and pathways for clozapine-related neutropaenia. Br J Clin Pharmacol 88(4):1904\u20131912","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2505_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/YCO.0000000000000440","volume":"31","author":"KJ Li","year":"2018","unstructured":"Li KJ, Solomon HV, DeLisi LE (2018) Clozapine pharmacogenomics: a review of efficacy, pharmacokinetics, and agranulocytosis. Curr Opin Psychiatry 31(5):403\u2013408","journal-title":"Curr Opin Psychiatry"},{"key":"2505_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-020-01018-w","volume":"21","author":"XN Li","year":"2020","unstructured":"Li XN, Zheng JL, Wei XH, Wang BJ, Yao J (2020) No association between the Ser9Gly polymorphism of the dopamine receptor D3 gene and schizophrenia: a meta-analysis of family-based association studies. BMC Med Genet 21:1\u20138","journal-title":"BMC Med Genet"},{"key":"2505_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116305","volume":"232","author":"X Li","year":"2023","unstructured":"Li X, Wei N, Song J, Liu J, Yuan J, Song R, Liu L, Mei L, Yan S, Wu Y (2023) The global burden of schizophrenia and the impact of urbanization during 1990\u20132019: an analysis of the global burden of disease study 2019. Environ Res 232:116305","journal-title":"Environ Res"},{"key":"2505_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136788","volume":"786","author":"C Liu","year":"2022","unstructured":"Liu C, Xu X, Liu X, Zhang T, Li Y, Yan P (2022) DRD3 Ser9Gly polymorphism and treatment response to antipsychotics in schizophrenia: a meta-analysis. Neurosci Lett 786:136788","journal-title":"Neurosci Lett"},{"issue":"1","key":"2505_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04008-9","volume":"22","author":"PM Llorca","year":"2022","unstructured":"Llorca PM, Nuss P, Fakra \u00c9, Alamome I, Drapier D, El Hage W, Azorin JM (2022) Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC Psychiatry 22(1):364","journal-title":"BMC Psychiatry"},{"key":"2505_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.667191","volume":"12","author":"B Ludwig","year":"2021","unstructured":"Ludwig B, Carlberg L, Kienesberger K, Swoboda P, Mitschek MM, Bernegger A, Schosser A (2021) Monoamino oxidase A gene single-nucleotide polymorphisms and methylation status and the risk of violent suicide attempts in affective disorder patients. Front Psychiatry 12:667191","journal-title":"Front Psychiatry"},{"issue":"10","key":"2505_CR68","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666201023154049","volume":"19","author":"J Ma","year":"2021","unstructured":"Ma J, Zhao M, Zhou W, Li M, Huai C, Shen L, Qin S (2021) Association between the COMT Val158Met polymorphism and antipsychotic efficacy in schizophrenia: an updated meta-analysis. Curr Neuropharmacol 19(10):1780","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"2505_CR69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/bcpt.13111","volume":"124","author":"L Ma","year":"2019","unstructured":"Ma L, Zhang X, Xiang Q, Zhou S, Zhao N, Xie Q, Cui Y (2019b) Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 124(1):94\u2013104","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"2505_CR70","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2217\/thy.10.3","volume":"7","author":"B Mackenzie","year":"2010","unstructured":"Mackenzie B, Souza R, Likhodi O, Tiwari A, Zai C, Sturgess J, M\u00fcller D (2010) Pharmacogenetics of antipsychotic treatment response and side effects. Therapy 7(2):191\u2013198. https:\/\/doi.org\/10.2217\/thy.10.3","journal-title":"Therapy"},{"key":"2505_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01003","volume":"11","author":"JC Martel","year":"2020","unstructured":"Martel JC, Gatti McArthur S (2020) Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia. Front Pharmacol 11:1003","journal-title":"Front Pharmacol"},{"key":"2505_CR72","doi-asserted-by":"crossref","unstructured":"Martin JLR, P\u00e9rez V, Sacrist\u00e1n M, Rodr\u00edguez-Artalejo F, Mart\u00ednez C, \u00c1lvarez E (2006) Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia: Submitted to European Psychiatry. A poster of this work was presented at the WPA International Congress in Florence (November 10\u201313, 2004). Poster session PO1: Psychotic Disorders.\u00a0Eur Psychiatry\u00a021(1):11\u201320","DOI":"10.1016\/j.eurpsy.2005.09.009"},{"issue":"27","key":"2505_CR73","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","volume":"28","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Chiappini S, Mosca A, Miuli A, Santovito MC, Pettorruso M, Giannantonio MD (2022) Atypical antipsychotic drugs in dual disorders: current evidence for clinical practice. Curr Pharm Des 28(27):2241\u20132259","journal-title":"Curr Pharm Des"},{"key":"2505_CR74","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.psychres.2018.03.029","volume":"264","author":"J Matsumoto","year":"2018","unstructured":"Matsumoto J, Nagaoka A, Kunii Y, Miura I, Hino M, Niwa S, Nawa H, Takahashi H, Kakita A, Yabe H (2018) Effects of the \u2212\u2009141C insertion\/deletion polymorphism in the dopamine D2 receptor gene on the dopamine system in the striatum in patients with schizophrenia. Psychiatr Res 264:116\u2013118","journal-title":"Psychiatr Res"},{"issue":"2","key":"2505_CR75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Marques TR, Howes OD (2020) Schizophrenia\u2014an overview. JAMA Psychiatr 77(2):201\u2013210","journal-title":"JAMA Psychiatr"},{"issue":"11","key":"2505_CR76","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","volume":"99","author":"A Mijovic","year":"2020","unstructured":"Mijovic A, MacCabe JH (2020) Clozapine-induced agranulocytosis. Ann Hematol 99(11):2477\u20132482","journal-title":"Ann Hematol"},{"issue":"1\u20133","key":"2505_CR77","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.schres.2008.01.007","volume":"100","author":"M Monakhov","year":"2008","unstructured":"Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V (2008) Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophr Res 100(1\u20133):302\u2013307","journal-title":"Schizophr Res"},{"key":"2505_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.815456","volume":"8","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee S, Skrede S, Milbank E, Andriantsitohaina R, L\u00f3pez M, Fern\u00f8 J (2022) Understanding the effects of antipsychotics on appetite control. Front Nutr 8:815456","journal-title":"Front Nutr"},{"issue":"2","key":"2505_CR79","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/tpj.2010.65","volume":"12","author":"DJ M\u00fcller","year":"2012","unstructured":"M\u00fcller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Kennedy JL (2012) Systematic analysis of dopamine receptor genes (DRD1\u2013DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 12(2):156\u2013164","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"2505_CR80","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","volume":"23","author":"S Nakajima","year":"2013","unstructured":"Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Foll BL, Mulsant B, Pollock B, Graff-Guerrero A (2013) The potential role of dopamine D3 receptor neurotransmission in cognition. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 23(8):799","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"2505_CR81","doi-asserted-by":"publisher","first-page":"10049","DOI":"10.1038\/s41598-020-67351-5","volume":"10","author":"M Nikolac Perkovic","year":"2020","unstructured":"Nikolac Perkovic M, Sagud M, Zivkovic M, Uzun S, Nedic Erjavec G, Kozumplik O, Pivac N (2020) Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. Sci Rep 10(1):10049","journal-title":"Sci Rep"},{"issue":"8","key":"2505_CR82","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1007\/s12035-015-9489-3","volume":"53","author":"C Noto","year":"2016","unstructured":"Noto C, Ota VK, Santoro ML, Gouvea ES, Silva PN, Spindola LM, Maes M (2016) Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic na\u00efve first episode psychosis. Mol Neurobiol 53(8):5701\u20135709","journal-title":"Mol Neurobiol"},{"key":"2505_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.08.016","volume":"131","author":"FC Nucifora Jr","year":"2019","unstructured":"Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A (2019) Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis 131:104257","journal-title":"Neurobiol Dis"},{"issue":"12","key":"2505_CR84","doi-asserted-by":"publisher","first-page":"30144","DOI":"10.3390\/ijms161226228","volume":"16","author":"Y Oda","year":"2015","unstructured":"Oda Y, Kanahara N, Iyo M (2015) Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci 16(12):30144\u201330163","journal-title":"Int J Mol Sci"},{"key":"2505_CR85","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241241922","volume":"12","author":"HSA Olasore","year":"2024","unstructured":"Olasore HSA, Oyedeji TA, Faleti JO, Ogundele OI, Olashore AA (2024) Association between dopamine receptor D2 Taq IA gene polymorphism (rs1800497) and personality traits. SAGE Open Med 12:20503121241241922. https:\/\/doi.org\/10.1177\/20503121241241922","journal-title":"SAGE Open Med"},{"key":"2505_CR86","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.schres.2025.03.005","volume":"277","author":"HSA Olasore","year":"2025","unstructured":"Olasore HSA, Faleti JO, Afe TO, Murtala AA, Olawale MO, Awesu AB, Igwo-Ezikpe MN, Magbagbeola OA, Olashore AA (2025) Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile. Schizophr Res 277:171\u2013176. https:\/\/doi.org\/10.1016\/j.schres.2025.03.005","journal-title":"Schizophr Res"},{"key":"2505_CR87","doi-asserted-by":"publisher","unstructured":"Orzelska-G\u00f3rka J, Mikulska J, Wiszniewska A, Bia\u0142a G (2022) New atypical antipsychotics in the treatment of schizophrenia and depression.\u00a0Int J Mol Sci 23(18):10624. https:\/\/doi.org\/10.3390\/ijms231810624","DOI":"10.3390\/ijms231810624"},{"key":"2505_CR88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12881-019-0773-3","volume":"20","author":"DZ Osmanova","year":"2019","unstructured":"Osmanova DZ, Freidin MB, Fedorenko OY, Pozhidaev IV, Boiko AS, Vyalova NM, Ivanova SA (2019) A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. BMC Med Genet 20:35\u201344","journal-title":"BMC Med Genet"},{"issue":"1\u20133","key":"2505_CR89","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2012.08.003","volume":"142","author":"VK Ota","year":"2012","unstructured":"Ota VK, Sp\u00edndola LN, Gadelha A, dos Santos Filho AF, Santoro ML, Christofolini DM, Belangero SI (2012) DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs. Schizophr Res 142(1\u20133):206\u2013208","journal-title":"Schizophr Res"},{"issue":"8","key":"2505_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/genes13081312","volume":"13","author":"DZ Paderina","year":"2022","unstructured":"Paderina DZ, Boiko AS, Pozhidaev IV, Mednova IA, Goncharova AA, Bocharova AV, Ivanova SA (2022) The gender-specific association of drd2 polymorphism with metabolic syndrome in patients with schizophrenia. Genes 13(8):1312","journal-title":"Genes"},{"key":"2505_CR91","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00213-021-05788-w","volume":"238","author":"V Peitl","year":"2021","unstructured":"Peitl V, \u0160tefanovi\u0107 M, Orlovi\u0107 I, Culej J, Renduli\u0107 A, Mate\u0161i\u0107 K, Karlovi\u0107 D (2021) Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology 238:1563\u20131573","journal-title":"Psychopharmacology"},{"key":"2505_CR92","doi-asserted-by":"crossref","unstructured":"Penedo MA, Rivera-Baltan\u00e1s T, P\u00e9rez-Rodr\u00edguez D, Allen J, Borrajo A, Alonso-Crespo D, Fern\u00e1ndez-Pereira C, Nieto-Araujo M, Ramos-Garc\u00eda S, Barreiro-Villar C, Caruncho HJ, Olivares JM, Ag\u00eds-Balboa RC (2021) The role of dopamine receptors in lymphocytes and their changes in schizophrenia. Brain, Behavior, & Immunity - Health pp. 12","DOI":"10.1016\/j.bbih.2021.100199"},{"key":"2505_CR93","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S455279","author":"A Peng","year":"2024","unstructured":"Peng A, Chai J, Wu H, Bai B, Yang H, He W, Zhao Y (2024) New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists. Neuropsychiatr Dis Treat. https:\/\/doi.org\/10.2147\/NDT.S455279","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"2505_CR94","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Howes OD (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64\u201377","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"2505_CR95","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/FPC.0000000000000314","volume":"28","author":"VM Rajagopal","year":"2018","unstructured":"Rajagopal VM, Rajkumar AP, Jacob KS, Jacob M (2018) Gene\u2013gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenet Genomics 28(1):31\u201335","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00702","volume":"9","author":"A Rampino","year":"2019","unstructured":"Rampino A, Marakhovskaia A, Soares-Silva T, Torretta S, Veneziani F, Beaulieu JM (2019) Antipsychotic drug responsiveness and dopamine receptor signaling; old players and new prospects. Front Psychiatry 9:702","journal-title":"Front Psychiatry"},{"key":"2505_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104894","volume":"142","author":"MJ Rantala","year":"2022","unstructured":"Rantala MJ, Luoto S, Borr\u00e1z-Le\u00f3n JI, Krams I (2022) Schizophrenia: the new etiological synthesis. Neurosci Biobehav Rev 142:104894","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"2505_CR98","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41380-021-01341-5","volume":"27","author":"ME Reith","year":"2022","unstructured":"Reith ME, Kortagere S, Wiers CE, Sun H, Kurian MA, Galli A, Lin Z (2022) The dopamine transporter gene SLC6A3: multidisease risks. Mol Psychiatry 27(2):1031\u20131046","journal-title":"Mol Psychiatry"},{"issue":"10","key":"2505_CR99","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00228-018-2498-1","volume":"74","author":"ELA Ribeiro","year":"2018","unstructured":"Ribeiro ELA, de Mendon\u00e7a Lima T, Vieira MEB, Storpirtis S, Aguiar PM (2018) Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol 74(10):1215\u20131233","journal-title":"Eur J Clin Pharmacol"},{"key":"2505_CR100","doi-asserted-by":"publisher","unstructured":"Sabe M, Zhao N, Crippa A, Kaiser S (2021) Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. NPJ schizophrenia 7(1):43. https:\/\/doi.org\/10.1038\/s41537-021-00171-2","DOI":"10.1038\/s41537-021-00171-2"},{"key":"2505_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010631.pub2","author":"KB Saha","year":"2016","unstructured":"Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU (2016) Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010631.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2505_CR102","doi-asserted-by":"publisher","unstructured":"Savitz J, Hodgkinson CA, Martin-Soelch C, Shen PH, Szczepanik J, Nugent A, Herscovitch P, Grace AA, Goldman D, Drevets WC (2013) The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting reward as well as movement. PloS one 8(1):e54108. https:\/\/doi.org\/10.1371\/journal.pone.0054108","DOI":"10.1371\/journal.pone.0054108"},{"issue":"1","key":"2505_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02998-6","volume":"14","author":"NT Sharew","year":"2024","unstructured":"Sharew NT, Clark SR, Schubert KO, Amare AT (2024) Pharmacogenomic scores in psychiatry: systematic review of current evidence. Transl Psychiatry 14(1):322","journal-title":"Transl Psychiatry"},{"issue":"6","key":"2505_CR104","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jpsychires.2008.09.005","volume":"43","author":"YC Shen","year":"2009","unstructured":"Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, Luu SU (2009) Effects of DRD2\/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 43(6):600\u2013606","journal-title":"J Psychiatr Res"},{"issue":"4","key":"2505_CR105","volume":"55","author":"S Soenarti","year":"2024","unstructured":"Soenarti S, Hadi MK (2024) Chlorpromazine-induced severe hyponatremia in 66 years old patient. Acta Med Indones 55(4):444","journal-title":"Acta Med Indones"},{"issue":"11","key":"2505_CR106","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0166-2236(99)01447-2","volume":"22","author":"R Spanagel","year":"1999","unstructured":"Spanagel R, Weiss F (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22(11):521\u2013527","journal-title":"Trends Neurosci"},{"issue":"9","key":"2505_CR107","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.euroneuro.2014.08.011","volume":"25","author":"WG Staal","year":"2015","unstructured":"Staal WG (2015) Autism, DRD3 and repetitive and stereotyped behavior, an overview of the current knowledge. Eur Neuropsychopharmacol 25(9):1421\u20131426","journal-title":"Eur Neuropsychopharmacol"},{"key":"2505_CR108","doi-asserted-by":"crossref","unstructured":"Stahl SM (2021). Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press","DOI":"10.1017\/9781108975292"},{"issue":"2","key":"2505_CR109","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-018-0494-8","volume":"32","author":"K Stegmayer","year":"2018","unstructured":"Stegmayer K, Walther S, van Harten P (2018) Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs 32(2):135\u2013147","journal-title":"CNS Drugs"},{"issue":"42","key":"2505_CR110","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1523\/JNEUROSCI.1062-10.2010","volume":"30","author":"C Stelzel","year":"2010","unstructured":"Stelzel C, Basten U, Montag C, Reuter M, Fiebach CJ (2010) Frontostriatal involvement in task switching depends on genetic differences in D2 receptor density. J Neurosci 30(42):14205\u201314212","journal-title":"J Neurosci"},{"issue":"10","key":"2505_CR111","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.cortex.2013.04.002","volume":"49","author":"C Stelzel","year":"2013","unstructured":"Stelzel C, Fiebach CJ, Cools R, Tafazoli S, D\u2019Esposito M (2013) Dissociable fronto-striatal effects of dopamine D2 receptor stimulation on cognitive versus motor flexibility. Cortex 49(10):2799\u20132811","journal-title":"Cortex"},{"key":"2505_CR112","doi-asserted-by":"crossref","unstructured":"Taheri N, Pirboveiri R, Sayyah M, Bijanzadeh M, Ghandil P (2023) Association of DRD2, DRD4 and COMT genes variants and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia. BMC Psychiatry pp. 23","DOI":"10.1186\/s12888-023-05292-9"},{"key":"2505_CR113","doi-asserted-by":"crossref","unstructured":"Tauscher J, Hussain T, Agid O, Verhoeff NPL, Wilson AA, Houle S, Kapur S (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.\u00a0Am J Psychiatry\u00a0161(9):1620\u20131625","DOI":"10.1176\/appi.ajp.161.9.1620"},{"issue":"5","key":"2505_CR114","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1570159X13666150115220221","volume":"13","author":"J Thomas","year":"2015","unstructured":"Thomas J, Caballero J, A Harrington C (2015) The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol 13(5):681\u2013691","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"2505_CR115","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000477153","volume":"24","author":"SR Thomson","year":"2017","unstructured":"Thomson SR, Chogtu B, Bhattacharjee D, Agarwal S (2017) Extrapyramidal symptoms probably related to risperidone treatment: a case series. Ann Neurosci 24(3):155\u2013163","journal-title":"Ann Neurosci"},{"issue":"1","key":"2505_CR116","first-page":"1","volume":"12","author":"B Torrico","year":"2022","unstructured":"Torrico B, Reif A, Cormand B (2022) Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders. Transl Psychiatry 12(1):1\u201310","journal-title":"Transl Psychiatry"},{"issue":"4","key":"2505_CR117","first-page":"212","volume":"5","author":"CC Toste","year":"2019","unstructured":"Toste CC, Duarte RR, Jeffries AR, Selvackadunco S, Troakes C, O\u2019Donovan MC, Bray NJ (2019) No effect of genome-wide significant schizophrenia risk variation at the DRD2 locus on the allelic expression of DRD2 in postmortem striatum. Mol Neuropsychiatry 5(4):212\u2013217","journal-title":"Mol Neuropsychiatry"},{"issue":"4","key":"2505_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/genes16040439","volume":"16","author":"M Treccani","year":"2025","unstructured":"Treccani M, Maggioni L, Di Giovanni C, Veschetti L, Cristofalo D, Patuzzo C, Lasalvia A, Ristic B, Kumar R, The PICOS-Veneto Group, Ruggeri M, Bonetto C, Malerba G, Tosato S (2025) A genome-wide association study of first-episode psychosis: a genetic exploration in an Italian cohort. Genes 16(4):439. https:\/\/doi.org\/10.3390\/genes16040439","journal-title":"Genes"},{"key":"2505_CR119","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"V Trubetskoy","year":"2022","unstructured":"Trubetskoy V, Pardi\u00f1as AF, Qi T (2022) Et al. mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604:502\u2013508. https:\/\/doi.org\/10.1038\/s41586-022-04434-5","journal-title":"Nature"},{"issue":"8","key":"2505_CR120","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.biopsych.2019.05.014","volume":"86","author":"EM Tunbridge","year":"2019","unstructured":"Tunbridge EM, Narajos M, Harrison CH, Beresford C, Cipriani A, Harrison PJ (2019) Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1\u20135, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol Psychiatry 86(8):608\u2013620","journal-title":"Biol Psychiatry"},{"issue":"8","key":"2505_CR121","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","volume":"15","author":"EW Tuplin","year":"2017","unstructured":"Tuplin EW, Holahan MR (2017) Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol 15(8):1192\u20131207","journal-title":"Curr Neuropharmacol"},{"issue":"7695","key":"2505_CR122","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature25758","volume":"555","author":"S Wang","year":"2018","unstructured":"Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL (2018) Structure of the D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE. Nature 555(7695):269. https:\/\/doi.org\/10.1038\/nature25758","journal-title":"Nature"},{"key":"2505_CR123","doi-asserted-by":"crossref","unstructured":"Wawrzczak-Bargie\u0142a A, Bilecki W, Ma\u0107kowiak M (2023) Epigenetic Targets in Schizophrenia Development and Therapy.\u00a0Brain Sci\u00a013(3)","DOI":"10.3390\/brainsci13030426"},{"issue":"1","key":"2505_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03499-w","volume":"15","author":"KCY Wong","year":"2025","unstructured":"Wong KCY, Leung PBM, Lee BKW, Zheng ZZY, Tsang EMW, Liu MH, So HC (2025) Pharmacogenetic study of antipsychotic\u2013induced lipid and BMI changes in Chinese schizophrenia patients: a genome-wide association study. Transl Psychiatry 15(1):295","journal-title":"Transl Psychiatry"},{"issue":"9","key":"2505_CR125","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1152\/jn.01005.2014","volume":"113","author":"Z Xie","year":"2015","unstructured":"Xie Z, Maddox WT, McGeary JE, Chandrasekaran B (2015) The C957T polymorphism in the dopamine receptor D2 gene modulates domain-general category learning. J Neurophysiol 113(9):3281\u20133290","journal-title":"J Neurophysiol"},{"key":"2505_CR126","doi-asserted-by":"crossref","unstructured":"Yang AC, Tsai J (2017) New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.\u00a0Int J Mol Sci\u00a018(8)","DOI":"10.3390\/ijms18081689"},{"key":"2505_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00355","volume":"13","author":"J Ye","year":"2019","unstructured":"Ye J, Ji F, Jiang D, Lin X, Chen G, Zhang W, Zhuo C (2019) Polymorphisms in dopaminergic genes in schizophrenia and their implications in motor deficits and antipsychotic treatment. Front Neurosci 13:355","journal-title":"Front Neurosci"},{"issue":"3","key":"2505_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030689","volume":"14","author":"J Ying","year":"2023","unstructured":"Ying J, Chew QH, McIntyre RS, Sim K (2023) Treatment-resistant schizophrenia, clozapine resistance, genetic associations, and implications for precision psychiatry: a scoping review. Genes 14(3):689","journal-title":"Genes"},{"issue":"Suppl 1","key":"2505_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492332","volume":"5","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, M\u00fcller DJ (2019) Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsychiatry 5(Suppl 1):1\u201326. https:\/\/doi.org\/10.1159\/000492332","journal-title":"Mol Neuropsychiatry"},{"issue":"6","key":"2505_CR130","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/schbul\/sbv116","volume":"41","author":"JP Zhang","year":"2015","unstructured":"Zhang JP, Robinson DG, Gallego JA, John M, Yu J, Addington J, Lencz T (2015) Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis. Schizophr Bull 41(6):1248\u20131255","journal-title":"Schizophr Bull"},{"key":"2505_CR131","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s12264-019-00432-2","volume":"35","author":"L Zhao","year":"2019","unstructured":"Zhao L, Wang H, Zhang Y, Wei J, Ni P, Ren H, Chinese Antipsychotics Pharmacogenomics Consortium (2019) Interaction between variations in dopamine D2 and serotonin 2A receptor is associated with short-term response to antipsychotics in schizophrenia. Neurosci Bull 35:1102\u20131105","journal-title":"Neurosci Bull"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-026-02505-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-026-02505-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-026-02505-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:02:28Z","timestamp":1783335748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-026-02505-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":131,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1007\/s12031-026-02505-0","relation":{},"ISSN":["1559-1166"],"issn-type":[{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"50"}}